Allan George F, Sui Zhihua
Johnson and Johnson Pharmaceutical Research and Development, Department of Reproductive Therapeutics, Raritan, NJ 08869, USA.
Nucl Recept Signal. 2003;1:e009. doi: 10.1621/nrs.01009. Epub 2003 Sep 27.
In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).
在过去几年中,组织选择性核受体配体的概念应运而生。随着雷洛昔芬等药物的成功上市,这一概念在雌激素领域得以实现。雷洛昔芬及其他选择性雌激素受体调节剂(SERM)的发现,增加了开发针对其他信号通路(包括雄激素,即选择性雄激素受体调节剂,或SARM)的选择性化合物的可能性。